FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SCHMERTZLER MICHAEL			2. Date of Event Requiring Statement (Month/Day/Year) 06/19/2013		3. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT]						
(Last) (First) (Middle) 1300 VALLEY ROAD					4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Street) NEW CANAAN (City)	CT (State)	06840 (Zip)				Officer (give title below)	Other (spe below)		Applicable Li X Form Form	ine) n filed b	t/Group Filing (Check by One Reporting Person by More than One Person
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)				2. Amount	t of Securities lly Owned (Instr. 4)	3. Ownership		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock						26,766	D				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securitie Underlying Derivative Security (4. Convers or Exerc	ise Form:	Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares	Price of Derivativ Security		irect	
Stock Option (right to buy)		(1)	05/15/2023	Co	ommon Stock	60,000	10.85	5 [)	
Stock Option (right to buy)			(2)	01/10/2022	Co	ommon Stock	276	218.4	I D)	
Stock Option (right to buy)			(3)	04/27/2021	Co	ommon Stock	276	490.8	3 [)	
Stock Option (right to buy)			(4)	02/02/2020	Co	ommon Stock	216	1,149.	6 Г)	
Stock Option (right to buy)			(4)	10/07/2019	Co	ommon Stock	266	508.8	3 [)	
Stock Option (right to buy)			(4)	01/25/2018	Co	ommon Stock	166	735.6	5 E)	
Stock Option (right to buy)			(4)	07/14/2018	Co	ommon Stock	83	735.6	5 [)	
Stock Option (right to buy)			(4)	04/18/2017	Co	ommon Stock	125	626.4	I D)	
Stock Option (right to buy)		(4)	03/01/2016	Co	ommon Stock	90	392.4	I D)	
Series Four Se	nior Preferred S	tock	(5)	(5)	Co	ommon Stock	276,853	(5)	I	[See Footnotes ⁽⁶⁾⁽⁷⁾
Series Four Senior Preferred Stock			(5)	(5)	Co	ommon Stock	155,366	(5)	I		See Footnote ⁽⁸⁾
Series Five Junior Preferred Stock			(9)	(9)	С	ommon Stock	1,980,029	(9)	I		See Footnotes ⁽¹⁰⁾⁽⁷⁾
Series Five Junior Preferred Stock			(9)	(9)	Co	ommon Stock	608,670	(9)	I		See Footnote ⁽⁸⁾

Explanation of Responses:

- 1. This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vesting on August 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
- 2. This option was granted on January 10, 2010 and vests over three years, with 8.33% of the shares underlying the option vesting on April 1, 2012 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
- 3. This option was granted on April 27, 2011 and vests over three years, with 8.33% of the shares underlying the option vesting on April 1, 2011 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
- 4. Currently exercisable.
- 5. The Series Four Senior Preferred Stock has no expiration date. Each share of Series Four Senior Preferred Stock will convert automatically into one share of Common Stock upon the closing of PTC Therapeutics, Inc.'s initial public offering without payment of further consideration.
- 6. Consists of (a) 216,209 shares held by Credit Suisse First Boston Equity Partners, L.P.; (b) 60,436 shares held by Credit Suisse First Boston Equity Partners (Bermuda), L.P.; and (c) 208 shares held by Credit Suisse First Boston U.S. Executive Advisors, L.P.
- 7. Mr. Schmertzler is a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P. Mr. Schmertzler disclaims beneficial ownership of the shares held by entities affiliated with Credit Suisse First Boston Equity Partners, L.P. except to the extent of any pecuniary interest therein.
- 8. Shares held directly by Section Six Partners, L.P. Mr. Schmertzler is a general and limited partner of, and trustee of certain family trusts holding interests in, Section Six Partners, L.P. Mr. Schmertzler
- disclaims beneficial ownership of the shares held by Section Six Partners, L.P. except to the extent of any pecuniary interest therein.

 9. The Series Five Junior Preferred Stock has no expiration date. Each share of Series Five Junior Preferred Stock will convert automatically into one share of Common Stock upon the closing of PTC
- Therapeutics, Inc.'s initial public offering without payment of further consideration.

 10. Consists of (a) 1,543,400 shares held by Credit Suisse First Boston Equity Partners, L.P.; (b) 431,419 shares held by Credit Suisse First Boston Equity Partners (Bermuda), L.P.; (c) 1,489 shares held by Credit Suisse First Boston U.S. Executive Advisors, L.P.; (d) 3,487 shares held by EMA Private Equity Fund 1999, L.P.; and (e) 234 shares held by Credit Suisse First Boston Finders & Screeners, L.P.

Remarks:

Exhibit Index: 24.1 Power of Attorney

/s/ Michael Schmertzler

** Signature of Reporting Person

06/19/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Limited Power Of Attorney For Section 16 Reporting Obligations

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of <u>Shane Kovacs</u>, <u>Mark E. Boulding</u>, <u>Donald Mankoff</u>, and <u>Kurt Andrews</u>, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of, and/or holder of equity in, PTC Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering Analysis and Retrieval System of the SEC;
- (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this June 19, 2013.

/s/ Michael Schmertzler

Signature

Name: Michael Schmertzler